Homoharringtonine

TargetMol
Product Code: TAR-T3380
Supplier: TargetMol
CodeSizePrice
TAR-T3380-5mg5mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3380-1mL1 mL * 10 mM (in DMSO)£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3380-10mg10mg£132.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3380-25mg25mg£170.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3380-50mg50mg£246.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3380-100mg100mg£323.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Homoharringtonine is an alkaloid inhibitor of protein synthesis with activity in myeloid malignancies. It might have clinical activity in some patients with myelodysplastic syndrome. Homoharringtonine enhances the paracellular permeability of Caco-2 cell monolayers by modulating the protein expression and localization of claudin isoforms. Homoharringtonine has anti-Y and antileukemic activities may have the potential ability to treat acute, chronic myeloid leukemia and Gefitinib-resistant NSCLC.
CAS:
26833-87-4
Formula:
C29H39NO9
Molecular Weight:
545.629
Pathway:
Stem Cells; JAK/STAT signaling
Purity:
0.9901
SMILES:
COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC
Target:
STAT

References

Qiu X, Zhang H, Tang Z, et al.Homoharringtonine promotes heart allograft acceptance by enhancing regulatory T cells induction in a mouse model.Chinese Medical Journal.2023: 10.1097. Cao W, et al. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. Sci Rep. 2015 Jul 13;5:8477. Wang F, Xie M, Chen P, et al. Homoharringtonine combined with cladribine and aclarubicin (HCA) in acute myeloid leukemia: A new regimen of conventional drugs and its mechanism. Oxidative Medicine and Cellular Longevity. 2022